ArticleAmerican journal of translational research2025
Clinical efficacy and prognostic analysis of autologous femoral head structural bone grafting combined with total hip arthroplasty for Crowe Type II/III developmental dysplasia of the hip in adults.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the clinical efficacy and mid-term outcomes of total hip arthroplasty (THA) assisted by acetabular reconstruction using autologous femoral head structural bone grafting in patients with Crowe type II/III developmental dysplasia of the hip (DDH).
methodsA retrospective analysis was conducted on 100 patients (100 hips) with Crowe type II/III DDH who underwent THA at the Affiliated Hospital of Xuzhou Medical University between January 2019 and December 2022. All patients received autologous femoral head structural bone grafting for acetabular reconstruction during the procedure. Perioperative parameters, visual analogue scale (VAS) scores, limb length discrepancy (LLD), range of motion (ROM), hip function [Harris hip score and Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)], incidence of complications, quality of life [Generic Quality of Life Inventory-74 (GQOLI-74)], and radiographic outcomes were assessed.
resultsThe mean follow-up duration was 10.78 ± 1.65 months. Postoperatively, the VAS score significantly decreased from 6.52 ± 2.58 to 1.73 ± 0.72 (P < 0.001), and the LLD reduced from 2.88 ± 0.54 cm to 0.92 ± 0.39 cm (P < 0.001). The Harris hip score increased from 58.23 ± 6.14 to 92.45 ± 5.82 (P < 0.001), while the WOMAC score decreased from 72.54 ± 8.61 to 18.34 ± 5.09 (P < 0.001). All domains of the GQOLI-74 score showed significant improvements (P < 0.001). The overall complication rate was 1.0%, and radiographic assessments confirmed bone healing.
conclusionTHA assisted by autologous femoral head structural bone grafting is a safe and effective approach for treating Crowe type II/III DDH. It significantly enhances hip function, restores biomechanics, improves the quality of life, and is associated with a low complication rate and favorable mid-term outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.